Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma
- PMID: 33112377
- PMCID: PMC7593880
- DOI: 10.1001/jamadermatol.2020.3677
Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma
Abstract
Importance: Until now, most studies on cutaneous squamous cell carcinoma (cSCC) incidence rates concerned only the first cSCC per patient. Given the increase in incidence rates and the frequent occurrence of subsequent cSCCs per patient, population-based data on the incidence rates of both first and multiple cSCCs are needed.
Objectives: To calculate annual age-standardized incidence rates for histopathologically confirmed first and multiple cSCCs per patient and to estimate future cSCC incidence rates up to 2027.
Design, setting, and participants: A nationwide population-based epidemiologic cohort study used cancer registry data on 145 618 patients with a first histopathologically confirmed cSCC diagnosed between January 1, 1989, and December 31, 2017, from the Netherlands Cancer Registry and all patients with multiple cSCCs diagnosed in 2017.
Main outcomes and measures: Age-standardized incidence rates for cSCC-standardized to the European Standard Population 2013 and United States Standard Population 2000-were calculated per sex, age group, body site, and disease stage. A regression model with positive slope was fitted to estimate cSCC incidence rates up to 2027.
Results: A total of 145 618 patients in the Dutch population (84 572 male patients [58.1%]; mean [SD] age, 74.5 [11.5] years) received a diagnosis of a first cSCC between 1989 and 2017. Based on incident data, European Standardized Rates (ESRs) increased substantially, with the highest increase found among female patients from 2002 to 2017, at 8.2% (95% CI, 7.6%-8.8%) per year. The ESRs for first cSCC per patient in 2017 were 107.6 per 100 000 person-years (PY) for male patients, an increase from 40.0 per 100 000 PY in 1989, and 68.7 per 100 000 PY for female patients, an increase from 13.9 per 100 000 PY in 1989, which corresponds with a US Standardized Rate of 71.4 per 100 000 PY in 2017 for men and 46.4 per 100 000 PY in 2017 for women. Considering multiple cSCCs per patient, ESRs increased by 58.4% for men (from 107.6 per 100 000 PY to 170.4 per 100 000 PY) and 34.8% for women (from 68.7 per 100 000 PY to 92.6 per 100 000 PY). Estimation of ESRs for the next decade show a further increase of 23.0% for male patients (ESR up to 132.4 per 100 000 PY [95% prediction interval, 125.8-139.0 per 100 000 PY]) and 29.4% for female patients (ESR up to 88.9 per 100 000 PY [95% prediction interval, 84.3-93.5 per 100 000 PY]).
Conclusions and relevance: This nationwide epidemiologic cohort study suggests that incidence rates of cSCC keep increasing, especially among female patients, and that the occurrence of multiple cSCCs per patient significantly adds to the current and future burden on dermatologic health care. Revision of skin cancer policies are needed to halt this increasing trend.
Conflict of interest statement
Figures


Comment in
-
Underestimation of Cutaneous Squamous Cell Carcinoma Incidence, Even in Cancer Registries.JAMA Dermatol. 2020 Dec 1;156(12):1290-1291. doi: 10.1001/jamadermatol.2020.3678. JAMA Dermatol. 2020. PMID: 33112371 No abstract available.
Similar articles
-
Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.JAMA Dermatol. 2020 Sep 1;156(9):973-981. doi: 10.1001/jamadermatol.2020.1988. JAMA Dermatol. 2020. PMID: 32609322 Free PMC article.
-
Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.JAMA Dermatol. 2019 Mar 1;155(3):298-306. doi: 10.1001/jamadermatol.2018.4219. JAMA Dermatol. 2019. PMID: 30484823 Free PMC article.
-
Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States.JAMA Dermatol. 2020 Nov 1;156(11):1192-1198. doi: 10.1001/jamadermatol.2020.2571. JAMA Dermatol. 2020. PMID: 32845319 Free PMC article.
-
Epidemiology of advanced cutaneous squamous cell carcinoma.J Eur Acad Dermatol Venereol. 2022 Jan;36(1):39-50. doi: 10.1111/jdv.17709. Epub 2021 Oct 11. J Eur Acad Dermatol Venereol. 2022. PMID: 34592000 Review.
-
Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.J Am Acad Dermatol. 2018 Feb;78(2):249-261. doi: 10.1016/j.jaad.2017.08.058. J Am Acad Dermatol. 2018. PMID: 29332705 Review.
Cited by
-
Limited impact of COVID-19-related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analysis.Br J Dermatol. 2022 Aug;187(2):196-202. doi: 10.1111/bjd.21050. Epub 2022 May 1. Br J Dermatol. 2022. PMID: 35141890 Free PMC article.
-
Temporal trends in the incidence rates of keratinocyte carcinomas from 1978 to 2018 in Tasmania, Australia: a population-based study.Discov Oncol. 2021 Aug 31;12(1):30. doi: 10.1007/s12672-021-00426-5. Discov Oncol. 2021. PMID: 35201459 Free PMC article.
-
Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data.Br J Dermatol. 2022 May;186(5):835-842. doi: 10.1111/bjd.20909. Epub 2022 Mar 26. Br J Dermatol. 2022. PMID: 34862598 Free PMC article.
-
Incidence and mortality rates of keratinocyte carcinoma from 1998-2017: a population-based study of sex differences in Ontario, Canada.CMAJ. 2021 Oct 4;193(39):E1516-E1524. doi: 10.1503/cmaj.210595. CMAJ. 2021. PMID: 34607845 Free PMC article.
-
[Assessment of an e‑learning platform for dermatosurgery].Dermatologie (Heidelb). 2022 Dec;73(12):943-951. doi: 10.1007/s00105-022-05054-w. Epub 2022 Sep 28. Dermatologie (Heidelb). 2022. PMID: 36169683 German.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous